Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 July 2021 | Story Lunga Luthuli | Photo Supplied
Fletcher Hiten, Chief Bioanalyst at FARMOVS, next to Aurora.

The Bioanalytical Services Division (BASD) at FARMOVS comprises a group of skilled and passionate scientists involved in the quantification of drugs, metabolites, and biomarkers in various biological matrices. One of their Analytical Science experts, Fletcher Hiten, explains what sets their team apart from the rest.

“Over the past 47 years, we have developed almost 600 validated assay methods. Most of these methods are for the analysis of ‘small’ molecules using chromatographic techniques such as LC-MS/MS, GC-MS, and HPLC, although LC-MS/MS is the technique of choice. New bioanalytical assays are continuously being development and validated in adherence to international regulatory guidelines set by the US-FDA and European Medicines Agency (EMA),” says Hiten.

“Recently, we decided to enhance our capabilities by recruiting exceptional talent. The newest member of the FARMOVS team is Aurora, a SCIEX Triple Quad™ 7500 LC-MS/MS mass analyser. Aurora is Latin for ‘dawn’: the beginning of a new era, especially one considered favourable. The SCIEX 7500 is currently marketed as the most sensitive triple quadrupole mass spectrometer available, allowing for sub-picogram/ml quantification. This means that Aurora will set FARMOVS apart from other clinical research organisations (CROs), creating an exciting and favourable landscape for clients to explore new partners in research.” 

Hiten stated: “If there was ever a time to move your next study to FARMOVS, it is now. To have Aurora on our team has many advantages, given that our clients can access unprecedented analytical sensitivity, which enables the quantification of pharmacokinetic (PK) profiles of drugs that have very low systemic absorption. These include predominantly local acting drugs, such as plasma concentrations of respiratory drugs (e.g., tiotropium and ipratropium), topically applied creams and ointments, and ophthalmology drops with ultra-sensitivity.”

“In addition, the quantification of drugs in low-volume matrices will also be exponentially enhanced, enabling the quantification of body fluids, where only a few microlitres can be collected, for example vaginal fluid, dried blood spots, cerebrospinal fluid, aqueous humour, synovial fluid, and epidermal micro-dialysis lysate – to name a few. The quantification of absorbed exogenous drugs into tissue, like vaginal biopsies and hair follicles, is also possible,” added Hiten. 

“And finally, multiple analyte analysis. In this case, the collected blood sample needs to be split into multiple aliquots for analysis, for example drug-drug interaction (DDI) studies with the Basel cocktail. The smaller sample volumes will allow more frequent sampling to be feasible and thus more accurate DDI interpretation,” Hiten explains.

“As a bio-analyst, one is seldom surprised. However, Aurora has already opened doors to new frontiers for our entire team and we cannot wait to do some more exploration,” says Hiten. 

To find out more about what Aurora and the FARMOVS team can do for your study, email business@farmovs.com

News Archive

UFS gets more than R3 Million for HIV/Aids activities
2007-12-13

 

In the picture are some of the members of the project team. From the left are: Mr Pieter du Plessis (Finances), Ms Estelle Heideman (HIV/Aids Co-ordinator: Lengau Agri Development Centre) and Rev Jaftha.
 

UFS gets more than R3 Million for HIV/Aids activities

The Chief Directorate: Community Service at the University of the Free State (UFS) has received more than R3 million to intensify activities regarding HIV/AIDS at all UFS campuses for the next seventeen months.

Higher Education HIV/AIDS Programme (HEAIDS) contributed R3 127 207 and the UFS R615 116 towards this initiative. The money will be used to implement intervention strategies from 1 January 2008 to 31 May 2009.

“The mandate poses an extensive challenge and puts pressure on the institution, but at the same time creates some incredible opportunities for intervention,” said the Chief Director of Community Service and Project Co-ordinator, Rev. Kiepie Jaftha.

HEAIDS is a nationally co-ordinated initiative to develop and strengthen the capacity of South African higher education institutions to respond to the causes, challenges and consequences of the HIV/AIDS pandemic in the sector. It is an initiative of the Department of Education and the implementing agency is Higher Education South Africa (HESA), an organisation representing vice-chancellors of tertiary institutions in South Africa.

The proposed areas and actions of intervention are categorised into three main components, namely:

- Prevention, treatment, care and support aimed at both students and staff on all UFS campuses.
Incorporation of HIV/AIDS issues into the teaching offerings of the UFS and the development of a formal policy in this regard.

- Implementation of an integrated management information system to empower stakeholders to make decisions and adapt actions by visualising facts, actions and progress on the overall HIV/AIDS programme.

The UFS met all the requirements of HEAIDS to qualify for this funding. A five-member team was formed to come up with a document entitled The Quest for an AIDS Competent Society that met the required standards.

“Each institution of higher learning had to identify and establish a project team, appoint a project leader, assign responsibilities to members of the team with different expertise, analyse the needs of the institution, and define and agree on projects in order to access the grant,” said Rev. Jaftha.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
13 December 2007

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept